Vaccibody is now public company listed on Euronext Merkur

VACCIBODY ENTERS INTO WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH GENENTECH, A MEMBER OF THE ROCHE GROUP, TO DEVELOP INDIVIDUALIZED NEOANTIGEN CANCER VACCINES
Vaccibody enters into worldwide, exclusive license and collaboration agreement with Genentech to develop VB10.NEO, individualized neoantigen cancer vaccines
OCTOBER 1, 2020

VACCIBODY LISTS ON OSLO STOCK EXCHANGE’S MERKUR MARKET
Vaccibody Lists on Oslo Stock Exchange’s Merkur Market
OCTOBER 7, 2020